surmount-1 tirzepatide obesity nejm 2022 weight loss percent Tirzepatide as Compared with Semaglutide for the Treatment of Obesity

In the SURMOUNT-4 trial, 82.5% of adults with obesity regained ≥25% of initial weight lost within one year of tirzepatide withdrawal; most showed reversal of cardiometabolic improvements. https://ja.ma/4qaMLfO

29.42

★★★★☆4.8 (126)

Once-weekly subcutaneous tirzepatide was not associated with an increased risk of depression compared with placebo, according to a post hoc analysis of the SURMOUNT clinical trial programme. The findings were published in

20.72

★★★★★4.9 (98)

Tirzepatide vs Semaglutide for Obesity – NEJM, May 2025 Relevant to endocrinology, internal medicine, cardiology, obesity medicine • Tirzepatide: −20.2% weight loss at 72 wks • Semaglutide: −13.7% • Greater waist reduction

20.43

★★★★★5.0 (157)

Mounjaro Weight Loss: What to Expect in the First Month

24.32

★★★★★4.7 (84)

Tirzepatide bests semaglutide for weight loss in adults with obesity

29.66

★★★★★4.9 (203)

In the SURMOUNT-4 trial, 82.5% of adults with obesity regained ≥25% of initial weight lost within one year of tirzepatide withdrawal; most showed reversal of cardiometabolic improvements. https://ja.ma/4qaMLfO

21.24

★★★★★5.0 (176)

Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial

28.30

★★★★★4.8 (132)